Despite Boston’s Q1 performance denoting a YoY rise of 11.2%, the company has trimmed its full-year growth outlook by 2% at the top-end.

AcuityMD plans to use AI to further advance its foundational platform designed for streamlining commercial execution protocols for medtech companies.

Medtronic has completed the acquisition of CathWorks, a company specialising in advancing the diagnosis and treatment of CAD, for $585m.

OEMs continue to prioritise high-growth segments of the medtech industry such as pulsed-field ablation (PFA), while conflict in the Middle East is impacting IPO activity.

BVI’s next-generation cataract and vitreoretinal procedure platform has been developed with features that are intended at improving patient outcomes.

Pulnovo Medical has completed an oversubscribed $100m strategic financing round, with Medtronic as the lead investor.

The funds from Trinity Capital are expected to advance commercialisation efforts for Cala Health’s device for alleviating tremors in Parkinson’s and essential tremor patients.

ScreenPoint’s Transpara AI is integrated with Siemens Healthineers tools, including syngo.Breast Care and its MAMMOMAT range.

Validated biomarkers help physicians identify patients that will benefit most from certain treatments, but implementation challenges remain.

Waters BD Onclarity HPV assay is intended to remove barriers that prevent individuals from receiving routine cervical cancer screening.

Avanos Medical is to be acquired by affiliates of AIP in an all-cash transaction that values the company at an enterprise value of $1.27bn.

Amplitude Vascular’s lead development product is an intravascular lithotripsy platform for calcified peripheral artery disease treatment.